AM-1714
 | |
| Systematic (IUPAC) name | |
|---|---|
| 1,9-dihydroxy-3-(2-methyloctan-2-yl)-6H-benzo[c]chromen-6-one | |
| Clinical data | |
| |
| Identifiers | |
| PubChem | CID 9950486 |
| ChemSpider |
8126097  |
| Chemical data | |
| Formula | C22H26O4 |
| 354.44 g/mol | |
|
SMILES
| |
| |
AM-1714 is a drug that acts as a reasonably selective agonist of the peripheral cannabinoid receptor CB2, with sub-nanomolar affinity and 490x selectivity over the related CB1 receptor. In animal studies it has both analgesic and anti-allodynia effects. The 9-methoxy derivative AM-1710 has similar CB2 affinity but only 54x selectivity over CB1.[1][2]
See also
References
- ↑ Khanolkar AD, Lu D, Ibrahim M, Duclos RI Jr, Thakur GA, Malan TP Jr, Porreca F, Veerappan V, Tian X, George C, Parrish DA, Papahatjis DP, Makriyannis A. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. Journal of Medicinal Chemistry. 2007 Dec 27;50(26):6493-500. PMID 18038967
- ↑ Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. Journal of Pharmacology and Experimental Therapeutics. 2008 Nov;327(2):584-91. doi: 10.1124/jpet.108.141994. PMID 18664590